fda glp-1 warning october 2025 Compound versions of drugs for weight loss halted by GLP-1 Safety Check - National
Description
These disparities can negatively impact the potential societal benefits of these medications in preventing diabetes-related complications
The patent expires in 2032 and covers any oral, injectable, or other drug containing semaglutide
Gastrointestinal effects represent the most common area of potential overlap
[DOI] [PMC free article] [PubMed] [Google Scholar] 54.Drucker D.J., Rosen C.F
Zelniker TA, Braunwald E
